| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/5000 | Human,Mouse,Rat |
| Aliases | DNMT3A2; M.HsaIIIA |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Fusion protein of human DNMT3A |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于DNMT3A抗体的3篇参考文献(示例为模拟内容，实际文献需根据具体数据库检索)：
---
1. **标题**：*DNMT3A in Hematopoiesis and Leukemia: Mechanisms and Clinical Implications*
**作者**：Ley TJ et al.
**摘要**：研究利用DNMT3A特异性抗体分析其在造血干细胞中的表达及功能，发现其突变导致DNA甲基化异常，与急性髓系白血病发生相关。
2. **标题**：*Antibody-Based Detection of DNMT3A Isoforms in Human Cancers*
**作者**：Yang L, et al.
**摘要**：开发高特异性DNMT3A抗体，用于区分不同剪接变体，揭示其在乳腺癌和结直肠癌中的差异表达及表观遗传调控作用。
3. **标题**：*Structural Insights into DNMT3A Auto-Inhibition and Activation by Histone Modifications*
**作者**：Zhang ZM, et al.
**摘要**：通过抗体介导的免疫沉淀技术，解析DNMT3A的自抑制构象及其受组蛋白H3K4me0修饰激活的分子机制。
---
(注：以上文献信息为示例，实际引用需以PubMed、Web of Science等数据库检索结果为准。)
DNMT3A (DNA methyltransferase 3A) is a critical enzyme responsible for establishing de novo DNA methylation patterns during embryonic development and cellular differentiation. It catalyzes the transfer of methyl groups to cytosine residues in CpG dinucleotides, a key epigenetic mechanism regulating gene expression, genomic imprinting, and chromatin stability. Unlike its homolog DNMT3B, DNMT3A is predominantly expressed in somatic cells and plays essential roles in maintaining cellular identity and silencing retrotransposons. Antibodies targeting DNMT3A are vital tools for studying its expression, localization, and functional interactions in both normal and pathological contexts.
DNMT3A mutations are frequently implicated in hematological malignancies, including acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), as well as in developmental disorders like Tatton-Brown-Rahman syndrome. Specific antibodies against DNMT3A enable researchers to detect protein levels via techniques such as Western blot, immunohistochemistry, and immunofluorescence, aiding in the identification of aberrant expression patterns or loss-of-function mutations. These reagents also support chromatin immunoprecipitation (ChIP) assays to map DNMT3A-binding sites and assess its role in shaping methylation landscapes.
The development and validation of high-quality DNMT3A antibodies remain crucial for advancing research in epigenetics, cancer biology, and therapeutic targeting, particularly in exploring DNMT3A's dual role as a tumor suppressor and oncogenic collaborator depending on cellular context.
×
